962 related articles for article (PubMed ID: 10804042)
1. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
2. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
3. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
4. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of slow release mesalazine.
De Vos M
Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
[TBL] [Abstract][Full Text] [Related]
6. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
7. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
8. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
11. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
12. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
13. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
14. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
[TBL] [Abstract][Full Text] [Related]
15. Systematic review: the use of mesalazine in inflammatory bowel disease.
Bergman R; Parkes M
Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
[TBL] [Abstract][Full Text] [Related]
16. MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.
Yang LP; McCormack PL
Drugs; 2011 Jan; 71(2):221-35. PubMed ID: 21275447
[TBL] [Abstract][Full Text] [Related]
17. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
Pokrotnieks J; Marlicz K; Paradowski L; Margus B; Zaborowski P; Greinwald R
Aliment Pharmacol Ther; 2000 Sep; 14(9):1191-8. PubMed ID: 10971236
[TBL] [Abstract][Full Text] [Related]
19. Extended-release mesalamine granules for ulcerative colitis.
Love BL; Miller AD
Ann Pharmacother; 2012 Nov; 46(11):1529-36. PubMed ID: 23115226
[TBL] [Abstract][Full Text] [Related]
20. A practical guide to the management of distal ulcerative colitis.
Ardizzone S; Bianchi Porro G
Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]